Antoine Salloum1,2,3, Jenna Koblinski1,2,3, Nagham Bazzi1,2,3, Nathalie C Zeitouni1,2,3. 1. Dr. Salloum is with the Department of Dermatology at Saint George Hospital University Medical Center in Beirut, Lebanon, and Dermatologic Surgicenter in Philadelphia, Pennsylvania. 2. Drs. Koblinski and Zeitouni are with the University of Arizona College of Medicine in Phoenix, Arizona. 3. Dr. Bazzi is with the Faculty of Medicine at Lebanese University in Beirut, Lebanon.
Abstract
BACKGROUND: Talimogene laherparepvec (T-VEC) is the first oncolytic virus therapy approved by the United States Food and Drug Administration (in 2015) for the treatment of advanced-stage melanoma. Despite a paucity of Phase III trials for T-VEC as a therapy for non-melanoma cancers, successful off-label use of T-VEC for this purpose has been reported in the literature. OBJECTIVE: We sought to review the literature describing T-VEC as a treatment for non-melanoma cancer. METHODS: Systematic searches of the PubMed literature database and ClinicalTrials.gov website were performed in July 2020, focusing on T-VEC in combination with non-melanoma cancer, including squamous cell carcinoma, Merkel cell carcinoma, sarcoma, cutaneous B-cell lymphoma, and cutaneous T-cell lymphoma. Articles were screened based on their title and abstract. RESULTS: Nine articles with 87 patients were included. Relevant articles included case reports, case series, and Phase I and Phase II trials. The majority of patients in the studies had refractory cancers or had been heavily pretreated. Overall, T-VEC demonstrated efficacy for non-melanoma cancer, both independently and in combination with biologics. CONCLUSION: T-VEC has demonstrated efficacy for non-melanoma cancers. Phase III trials of T-VEC for this indication are warranted to expand its clinical utility.
BACKGROUND: Talimogene laherparepvec (T-VEC) is the first oncolytic virus therapy approved by the United States Food and Drug Administration (in 2015) for the treatment of advanced-stage melanoma. Despite a paucity of Phase III trials for T-VEC as a therapy for non-melanoma cancers, successful off-label use of T-VEC for this purpose has been reported in the literature. OBJECTIVE: We sought to review the literature describing T-VEC as a treatment for non-melanoma cancer. METHODS: Systematic searches of the PubMed literature database and ClinicalTrials.gov website were performed in July 2020, focusing on T-VEC in combination with non-melanoma cancer, including squamous cell carcinoma, Merkel cell carcinoma, sarcoma, cutaneous B-cell lymphoma, and cutaneous T-cell lymphoma. Articles were screened based on their title and abstract. RESULTS: Nine articles with 87 patients were included. Relevant articles included case reports, case series, and Phase I and Phase II trials. The majority of patients in the studies had refractory cancers or had been heavily pretreated. Overall, T-VEC demonstrated efficacy for non-melanoma cancer, both independently and in combination with biologics. CONCLUSION: T-VEC has demonstrated efficacy for non-melanoma cancers. Phase III trials of T-VEC for this indication are warranted to expand its clinical utility.
Authors: Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin Journal: J Clin Oncol Date: 2015-05-26 Impact factor: 44.544
Authors: Claire-Audrey Y Bayan; Adriana T Lopez; Robyn D Gartrell; Kimberly M Komatsubara; Margaret Bogardus; Nisha Rao; Cynthia Chen; Thomas D Hart; Thomas Enzler; Emanuelle M Rizk; Jaya Sarin Pradhan; Douglas K Marks; Larisa J Geskin; Yvonne M Saenger Journal: Curr Oncol Rep Date: 2018-08-25 Impact factor: 5.075
Authors: Matthew C Perez; John T Miura; Syeda Mahrukh Hussnain Naqvi; Youngchul Kim; Amanda Holstein; Daniel Lee; Amod A Sarnaik; Jonathan S Zager Journal: Ann Surg Oncol Date: 2018-10-08 Impact factor: 5.344
Authors: Ciara M Kelly; Cristina R Antonescu; Timothy Bowler; Rodrigo Munhoz; Ping Chi; Mark A Dickson; Mrinal M Gounder; Mary Louise Keohan; Sujana Movva; Reena Dholakia; Hamza Ahmad; Matthew Biniakewitz; Mercedes Condy; Haley Phelan; Margaret Callahan; Phillip Wong; Sam Singer; Charlotte Ariyan; Edmund K Bartlett; Aimee Crago; Sam Yoon; Sinchun Hwang; Joseph P Erinjeri; Li-Xuan Qin; William D Tap; Sandra P D'Angelo Journal: JAMA Oncol Date: 2020-03-01 Impact factor: 33.006